Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot

Vange, N. van der; Goethem, A.R. van; Zoetmulder, F.A.N.; Kaag, M.; Vaart, P.J.M. van de; Huinink, W.W. ten Bokkel; Beijnen, Jos H.

doi:10.1053/ejso.2000.0978

Cited by 63 publications

(29 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with complete cytoreduction are then randomized to receive HIPEC or no HIPEC. A similar multicenter phase III randomized trial in the interval setting has just started in Italy (CHORINE: Cytoreduction and HIPEC in the treatment of OvaRIaN cancEr) [58].…”

Section: Hipec As First Line Therapy For Ovarian Cancermentioning

confidence: 99%

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.

show abstract

Section: Hipec As First Line Therapy For Ovarian Cancermentioning

confidence: 99%

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Peritoneal surgeons currently evaluate such patients using the Peritoneal Cancer Index (PCI) [6]. The Lyon staging system first described by Gilly et al [7] or the Dutch scores [8 ]are also used for the treatment of patients with peritoneal carcinomatosis. Although these assessments are objective, they seem complicated for general surgeons who do not usually perform aggressive surgical cytoreduction for peritoneal carcinomatosis.…”

Section: Introductionmentioning

confidence: 99%

Validation and Clinical Use of the Japanese Classification of Colorectal Carcinomatosis: Benefit of Surgical Cytoreduction Even without Hyperthermic Intraperitoneal Chemotherapy

et al. 2010

View full text Add to dashboard Cite

Background: This study aimed to validate an easy to use practical classification of peritoneal metastasis arising from colorectal cancer. Patients and Methods: Data from 2,134 consecutive patients who underwent resection for colorectal cancer at a single institution were reviewed. Peritoneal metastasis was classified depending on extent into three groups (P1–P3). The macroscopic radical resection rates and survival of patients with colorectal cancer complicated with peritoneal metastasis were analyzed. Results: Of the 2,134 patients, 116 (5.4%) had peritoneal metastasis. Among them, 20 (17.2%) underwent macroscopic radical resection. Tumor location on the right side was associated with more extensive peritoneal metastasis (p = 0.010). Male gender (p = 0.0027), liver metastasis (p = 0.0021), and P3 peritoneal metastasis were independent risk factors for noncurative resection. The Cox proportional hazards model showed that gender (p = 0.031), operation period (p = 0.031), and macroscopic radical resection for colorectal cancer and peritoneal metastasis (p = 0.031) were independent prognostic factors. Conclusions: Being female with left colon cancer complicated with P1 or P2 peritoneal metastasis is a good indicator for macroscopic radical resection if liver metastasis is absent. The present classification helped to determine surgical indication for patients with colorectal cancer complicated with synchronous peritoneal metastasis in routine clinical practice.

show abstract

“…The peri-operative mortality rate for CRS and HIPEC was 3.7% (8/236 cases) [50,[53][54][55]58,60,[62][63][64][65]67,68] compared with 1.4% (0-3.4%) out of 631 patients undergoing CRS for recurrent EOC [88]. Neither the risks nor risk/benefit ratio associated with HIPEC þ CRS versus CRS alone have been clearly defined.…”

Section: Recurrencementioning

confidence: 99%

“…Where postoperative morbidity information for CRS þ HIPEC in recurrent/persistent EOC is detailed in Table III [50,[53][54][55]58,60,[62][63][64][65]67,68] grade 3 or 4 hematologic toxicity was 4.7% (11/236) and raised creatinine, mainly associated with the use of cisplatin, was 3.4% (8/236). The rate of anastomotic leaks was 1.7% (4/236) and gastrointestinal perforations 2.5% (6/236).…”

Section: Recurrencementioning

confidence: 99%

Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer

Helm

Bristow

Kusamura³

et al. 2008

Journal of Surgical Oncology

View full text Add to dashboard Cite

Women with epithelial ovarian cancer (EOC) usually present with advanced disease and overall only just over half survive 5 years. Even following a complete response to front-line treatment two-thirds will recur, with a resultant dismal prognosis. We review and discuss the role of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in EOC and present the results of the ovary consensus panel (OCP) convened for the 5th International Workshop on Peritoneal Surface Malignancy.

show abstract

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot

Cited by 63 publications

References 13 publications

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Validation and Clinical Use of the Japanese Classification of Colorectal Carcinomatosis: Benefit of Surgical Cytoreduction Even without Hyperthermic Intraperitoneal Chemotherapy

Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer

Contact Info

Product

Resources

About